If CBSF was modified by ligands that specifically identify lung cancer cells (e.g., transferrin, transformation factor α, hyaluronic acid, folic acid, and peptides) and used to package pDNA, the complex is expected to further inhibit the proliferation of cancer cells [46,47]. Here, TF is linked to lung carcinoma.